Ameresco Reports Increased Q1 Loss Amid Revenue Growth, Details Biogas JV Capital Infusion

summarizeSummary

Ameresco reported a wider net loss in Q1 2026 despite revenue growth, but detailed a significant capital infusion from its new biogas joint venture and showed strong operating cash flow improvement.

check_boxKey Events

• Q1 Financial Performance

  Reported a net loss of $14.38 million ($0.35 per share) for Q1 2026, a significant increase from $5.61 million ($0.10 per share) in Q1 2025, despite a 13.8% revenue increase to $401.46 million. Operating income decreased by 25.2% year-over-year.

• Strong Operating Cash Flow Improvement

  Generated $35.40 million in cash from operating activities in Q1 2026, a substantial positive shift from a $28.30 million outflow in the prior year period.

• Biogas Joint Venture Capital Infusion Details

  Provided further details on the Neogenyx Fuels LLC joint venture with HASI, confirming a $400 million investment, with $100 million paid directly to Ameresco and $58 million allocated to reduce existing project-level debt. This capital infusion is expected to fund growth, working capital, and deleveraging.

• Increased Backlog

  Total project backlog grew to $5.27 billion as of March 31, 2026, up from $4.90 billion in the prior year, indicating strong future revenue potential.

auto_awesomeAnalysis

Ameresco's Q1 2026 results present a mixed financial picture. While the company achieved strong revenue growth and a significant turnaround in operating cash flow, its net loss widened considerably, and operating income declined. The detailed breakdown of the recently announced Neogenyx Fuels joint venture, particularly the $100 million cash payment to Ameresco and $58 million for debt reduction, is a crucial positive development, providing much-needed capital and improving liquidity. However, investors should remain cautious due to the ongoing dispute over $89 million in liquidated damages with SCE, the potential loss of $26.68 million from a bankrupt supplier, and new regulatory changes that could impact future tax credits. The increased backlog is a positive long-term indicator, but near-term profitability and risk management remain key areas to monitor.